Hot Stock Analysis of Giant Biogene (02367.HK) on December 30, 2025

Giant Biogene (02367.HK) became a hot stock in Hong Kong on December 30, 2025, mainly affected by multiple factors. First, China Merchants Securities International downgraded the company’s rating from ‘Overweight’ to ‘Neutral’ and lowered its 2025-27 revenue forecast by an average of 30%, reflecting the management’s latest guidance and a more prudent growth outlook for 2026 [3]. This negative news directly led to a drop of over 3% in the stock price in the afternoon, becoming the focus of market attention that day. Second, the company conducted a share repurchase operation on December 23 [1], showing the management’s certain recognition of the company’s value, which had previously attracted investors’ attention. In addition, southbound funds have maintained a net purchase of this stock in the past half month [4], indicating that mainland investors are still interested in its long-term development. From the sector perspective, Giant Biogene belongs to the consumer non-cyclical industry, mainly engaged in personal and household goods and services [2]. As of that day, the stock price closed at HK$34.16, a significant drop from the 52-week high of HK$87.10, approaching the 52-week low of HK$34.04 [2], with a trading volume of 2.706 million shares and a turnover of HK$96.52 million [1].

1. There is an obvious divergence between institutional and investor sentiment: institutions are cautious about the short-term growth prospects due to the lowered revenue forecast and rating [3], while share repurchases and continuous inflow of southbound funds reflect some investors’ recognition of the company’s long-term value, forming the current long-short game situation.
2. The stock price is close to the important support of the 52-week low: the 52-week low of HK$34.04 becomes a key support level [2]. If this support level is broken, it may trigger further downward pressure; if it can be held, it may indicate the possibility of a short-term bottom rebound.
3. Industry competition becomes a long-term hidden concern: as a participant in the recombinant collagen industry, the company faces the challenge of intensified industry competition, which may affect market share and profitability [2], which is a factor that investors need to pay long-term attention to.

• Risks
  : Performance growth pressure increases; institutions’ lowered revenue forecast indicates that the company needs to deal with the challenges of industry competition and slow growth [3]; valuation risk exists: although the stock price is close to the 52-week low, it is necessary to re-evaluate the rationality of valuation based on the latest performance [2]; intensified industry competition may affect the company’s future profitability [2].
• Opportunities
  : Share repurchases show the management’s confidence in the company’s value; if the company can achieve performance growth exceeding market expectations, it may drive the stock price to rebound; the continuous buying of southbound funds also provides certain support for the stock price [4].

Giant Biogene (02367.HK) became a hot stock in Hong Kong due to rating downgrade and revenue forecast cut. The current stock price is close to the 52-week low, and market sentiment shows a divergence between institutional caution and some investors’ long-term optimism. The 52-week low of HK$34.04 is a key short-term support level. The company faces performance growth pressure and industry competition challenges, but there are also opportunities brought by share repurchases and southbound fund inflows. Investors need to pay attention to the subsequent changes in the company’s performance and industry competition situation.